UroGen Pharma

  • Booth: 6471, 6779

Welcome to Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies with a focus on uro-oncology. The lead product candidates are investigational new drug formulations of the chemotherapy agent mitomycin (MMC). UroGen is developing novel formulations as chemoablation agents, which means they are designed to ablate tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, or UTUC, and low-grade bladder cancer.

The lead products are formulated using UroGen’s proprietary reverse thermal gel technology, RTGELTM, a gel technology which is liquid at lower temperatures but converts to a semi-solid state at body temperature. The liquid characteristics are thought to aid in drug delivery while the conversion to the semisolid state following instillation is believed to result in longer retention of the mitomycin in the bladder or upper urinary tract compared to regular instillation. The formulation is thought to enable a prolonged exposure of tumor tissue to mitomycin.


Brands: MITOGEL™ (mitomycin) urothelial gel, 0.4% for UTUC. VESIGEL™ (mitomycin) urothelial gel, 0.18% for LG-NMIBC. VESIMUNE™ (imiquimod) for HG-NMIBC.